Data as of Mar 07
| -0.08 / -1.52%|
The 5 analysts offering 12-month price forecasts for Protalix Biotherapeutics Inc have a median target of 6.00, with a high estimate of 8.00 and a low estimate of 4.50. The median estimate represents a +15.83% increase from the last price of 5.18.
The current consensus among 6 polled investment analysts is to Hold stock in Protalix Biotherapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.